Splicing factor 3B subunit 1 <scp> <i>(SF3B1)</i> </scp> mutation in the context of <scp>therapy‐related</scp> myelodysplastic syndromes-Reference-Cited by-同舟云学术

Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy‐related myelodysplastic syndromes

Published:2022-06-24 Issue:4 Volume:198 Page:713-720
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Volpe Virginia O.¹^ORCID,Al Ali Najla¹,Chan Onyee¹,Padron Eric¹,Sallman David A.¹,Kuykendall Andrew¹^ORCID,Sweet Kendra¹,Lancet Jeffrey E.¹,Komrokji Rami S.¹^ORCID

Affiliation:

1. Department of Malignant Hematology H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18319

Reference18 articles.

2. The evolving challenge of therapy-related myeloid neoplasms

3. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

4. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series

5. Therapy-related myeloid neoplasms

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. An intricate rewiring of cancer metabolism via alternative splicing;Biochemical Pharmacology;2023-11

3. SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process;Frontiers in Oncology;2023-03-17

4. Co-mutation ofASXL1andSF3B1Predicts Poorer Overall Survival Than IsolatedASXL1orSF3B1Mutations;In Vivo;2023